Does cooking destroy the anti-cancer compounds in oyster mushrooms?

For the most potent fraction identified in this literature, yes. Gu and Sivam (2006) found the cytotoxic activity of oyster mushroom extract against prostate cancer cells remained stable below 40°C but was eliminated by two hours at 80°C, and they characterised the active component as a water-soluble protein or polypeptide. Ordinary sauteing, roasting, and boiling all exceed 80°C. Beta-glucans are considerably more heat-stable and are not affected in the same way, but the specific proteins behind the strongest in vitro results are unlikely to survive normal cooking. No study has tested whether these proteins survive digestion even when eaten raw.

Oyster Mushroom Cancer Research: What the Studies Found

Oyster Mushroom & Cancer

4 cancer cell lines, 0 normal lines affected

Oyster mushroom extract suppressed proliferation of two breast and two colon cancer cell lines while leaving matched normal breast and colon cells unaffected in the same experiment. Breast and colon were the only cancer types this study tested.

Jedinak & Sliva, International Journal of Oncology, 2008 (PMID 19020765)

MCF-7 + MDA-MB-231

both breast cancer cell lines inhibited. MDA-MB-231 is triple-negative, the hardest subtype to treat (Jedinak & Sliva, 2008)

Below 40°C

the temperature ceiling for the active fraction. Two hours at 80°C abolished the anti-cancer activity entirely (Gu & Sivam, 2006)

In remission

the only human data comes from stage I-II breast cancer patients already in remission, and measured immune cell counts, not tumour outcomes (Spacek et al., 2022)

Jedinak & Sliva, International Journal of Oncology, 2008 (PMID 19020765)

View as image ↗

The first thing that stands out in the oyster mushroom cancer research is not the cell death data. It is the selectivity data. In the landmark 2008 study by Jedinak and Sliva, oyster mushroom extract inhibited proliferation in four cancer cell lines. In the same experiment, it did not affect the matched normal cell lines from the same tissues.

That distinction, cancer cells affected and normal cells unaffected, is what makes this body of research interesting enough to examine carefully. Cancer drugs that kill cancer cells but spare normal tissue are the goal of oncology drug development. Oyster mushroom extract is far from a proven cancer drug. But the selectivity finding is real, and it is the starting point for understanding what the research actually says about oyster mushrooms and cancer.

For the broader oyster mushroom picture, see What Is Oyster Mushroom? The World's Second Most Popular Mushroom. For the population-level cancer prevention data, see Oyster Mushroom as a Cancer-Preventive Food: Epidemiological Data.

Key Takeaways

Oyster mushroom extract suppressed proliferation of breast cancer cells (MCF-7 and MDA-MB-231) and colon cancer cells (HT-29 and HCT-116) without affecting matched normal cells (MCF-10A and FHC) in the same laboratory experiment (Jedinak & Sliva, IJOC, 2008). That study tested breast and colon only; prostate and liver findings come from separate, older papers
MDA-MB-231 is a triple-negative breast cancer cell line, the most aggressive and treatment-resistant subtype, making this finding more notable than activity against hormone-positive lines alone
The active fraction is heat-sensitive. Two hours at 80°C abolished the anti-cancer activity of oyster mushroom extract, which stayed stable only below 40°C, and the active compounds behaved like water-soluble proteins rather than polysaccharides (Gu & Sivam, J Med Food, 2006)
King Oyster mushroom (Pleurotus eryngii) protein inhibited colon cancer cells in both cell culture and in a mouse tumor model, and spared normal human colon cells, providing the only in vivo validation for the Pleurotus colon cancer data (Yuan et al., Food & Function, 2017)
The only human data: pleuran (Pleurotus ostreatus beta-glucan) raised T- and B-lymphocyte counts in stage I-II breast cancer patients already in remission, compared with an untreated control group. No tumour outcome was measured (Spacek et al., Immunotherapy, 2022)
Four compound classes are proposed to drive the activity, but they rest on very different evidence: beta-glucans have human data, lectins have mouse tumour data, ergothioneine has only population-level association, and lovastatin has no anti-cancer evidence in oyster mushrooms at all, and was undetectable in one analysis
All cell-killing evidence comes from laboratory studies. No trial has demonstrated that eating oyster mushrooms or taking oyster mushroom supplements kills cancer cells in humans.

The Selectivity Finding: Cancer Cells Killed, Normal Cells Unharmed

In 2008, Andrej Jedinak and Daniel Sliva published the central paper in oyster mushroom and cancer research. Their screen actually began with four edible species, comparing Agaricus bisporus (portabella), Flammulina velutipes (enoki), Lentinula edodes (shiitake), and Pleurotus ostreatus. Oyster mushroom was the most potent of the four, which is why the paper carries its name. They then tested a water extract of P. ostreatus against four cancer cell lines and two matched normal cell lines. The cancer lines were MCF-7 and MDA-MB-231 (breast cancer), and HT-29 and HCT-116 (colon cancer). The normal lines were MCF-10A (normal breast epithelial) and FHC (normal colon epithelial).

The extract inhibited proliferation in all four cancer cell lines. It produced no measurable effect on either normal cell line at the same concentrations.^[1]

One detail is worth keeping in view, because it is the single most common distortion of this paper: Jedinak and Sliva tested breast and colon cancer only. The oyster mushroom results for prostate and liver cancer come from different research groups, in different years, using different preparations. Summaries that credit a single 2008 study with four cancer types are merging four separate literatures into one sentence.

Attribution Check

Four Cancer Types, Four Separate Papers

The familiar summary — “oyster mushroom kills breast, colon, prostate and liver cancer cells” — merges four studies published across seventeen years, using three different preparations. The 2008 study that carries the famous selectivity result tested breast and colon only.

Oyster mushroom cancer studies by cancer type, cell lines tested, preparation, model system, normal-cell control, and source study
Cancer	What was tested	Model	Normal-cell control	Source
Breast	MCF-7, MDA-MB-231 P. ostreatus water extract	Cells in a dish	MCF-10A unaffected	Jedinak & Sliva [1]2008
Colon	HT-29, HCT-116 P. ostreatus water extract	Cells in a dish	FHC unaffected	Jedinak & Sliva [1]2008
Colon	HCT-116, MC38 P. eryngii protein (PEP)	Dish + live mice	CCD-18Co unaffected	Yuan [3]2017
Prostate	PC-3 P. ostreatus water extract (POE)	Cells in a dish	None reported	Gu & Sivam [2]2006
Liver	Hepatoma H-22 (+ sarcoma S-180) P. ostreatus lectin	Live mice only	None reported	Wang, Gao & Ng [7]2000

No row is a human study. The liver row is the one most often misdescribed: H-22 hepatoma was grown as a tumour inside living mice and treated with an isolated lectin, not run as a hepatoma cell line in culture.

Sources: Jedinak A, Sliva D. Int J Oncol. 2008;33(6):1307–13 (PMID 19020765); Gu YH, Sivam G. J Med Food. 2006;9(2):196–204 (PMID 16822205); Yuan B, et al. Food Funct. 2017;8(10):3553–3562 (PMID 28880032); Wang H, Gao J, Ng TB. Biochem Biophys Res Commun. 2000;275(3):810–6 (PMID 10973803). Cell lines, model systems and normal-cell controls taken directly from each published abstract.

The mechanism differed between the two cancer types. Flow cytometry showed the extract arrested both MCF-7 and HT-29 cells at the G0/G1 phase of the cell cycle. In MCF-7 breast cancer cells, it did so by inducing p53 expression, upregulating p21 (which halts cell division), and inhibiting Rb phosphorylation (which prevents the cell from progressing through the cycle). This is a p53-dependent pathway. In HT-29 colon cancer cells, the extract upregulated p21 and inhibited Rb phosphorylation in the same way, but without engaging p53. Same brake, different lever: a p53-independent mechanism.

That mechanistic difference matters. Roughly half of all human cancers carry a mutated, non-functional p53, a figure that has been broadly consistent across cancer genomics surveys for decades. A compound that can only act through p53 activation would be inert against that half. Oyster mushroom extract showed activity through both a p53-dependent and a p53-independent route within a single experiment, which is part of why this paper is cited as heavily as it is. For the deeper p53 mechanism analysis, see Pleurotus ostreatus and p53 Tumor Suppression.

Breast Cancer Research: MCF-7 and Triple-Negative MDA-MB-231

Two breast cancer cell lines, not one. This matters because they represent different subtypes of breast cancer.

MCF-7 cells are estrogen receptor-positive (ER+). This is the most common breast cancer subtype. It grows in response to estrogen, and hormone therapy can slow or stop it. Therapies targeting the estrogen receptor are well-established. The MCF-7 finding establishes that oyster mushroom extract works against hormone-positive breast cancer in cell culture.

MDA-MB-231 cells are triple-negative breast cancer: they lack estrogen receptors, progesterone receptors, and HER2 overexpression. Triple-negative is the subtype with the fewest targeted therapy options. Chemotherapy is the primary treatment. The response to many novel compounds is often absent in triple-negative lines even when other breast cancer lines respond.

Oyster mushroom extract inhibited both. The MDA-MB-231 finding is the more striking of the two because this cell line is the harder target.^[1]

A 2020 review by Wong and Ng surveyed mushrooms with anti-breast-cancer activity across cell culture, animal, and clinical settings, and oyster mushroom is one of roughly eighteen species it covers.^[4] Being on that list places oyster mushroom in reasonable company, but the review does not rank it as the most potent, and the more telling detail is which species it names separately as having demonstrated antineoplastic effectiveness in human clinical trials: Antrodia camphorata, Cordyceps sinensis, Coriolus versicolor, Ganoderma lucidum, Grifola frondosa, and Lentinula edodes. Pleurotus ostreatus is not among them.^[4]

Colon Cancer: Two Species, Two Models, One Consistent Pattern

Jedinak's 2008 study used two colon cancer cell lines, HT-29 and HCT-116. Both showed inhibited proliferation. The p53-independent mechanism in HT-29 established that oyster mushroom compounds could arrest colon cancer cells through a pathway distinct from the breast cancer mechanism.

The colon cancer data was extended in 2017 by Yuan and colleagues, who tested Pleurotus eryngii (King Oyster mushroom, a related species) rather than Pleurotus ostreatus. They isolated a protein from King Oyster, designated PEP, and tested it in human HCT-116 and mouse MC38 colon cancer cells, then in a mouse tumor model. PEP suppressed proliferation in both cell lines in a dose- and time-dependent way, and produced no inhibition of normal human colonic myofibroblasts (CCD-18Co) at the same concentrations. In mice, PEP treatment significantly suppressed the growth of allograft colon tumors.^[3]

That second selectivity result is the most useful thing in the 2017 paper. It means the cancer-versus-normal-cell pattern Jedinak reported in 2008 was not a one-off property of one extract in one laboratory: a different species, a different purified compound, and a different normal-cell control produced the same shape of result nearly a decade later.

The mechanisms do not line up neatly, though. Jedinak's colon result was explicitly p53-independent. Yuan's PEP worked in the opposite direction, upregulating p53 along with p21 and caspase-3 in the treated tumors.^[3] Two Pleurotus preparations can therefore arrest the same cancer type through different molecular routes, which is a reminder that "oyster mushroom compounds" is a category, not a single drug.

The animal model finding is one step closer to human relevance than cell culture, but still far from clinical evidence. Tumor-bearing mice respond differently to treatments than humans do, and the translation failure rate from animal cancer models to human clinical benefit is high historically. This is not a reason to dismiss the finding, but it is the context for interpreting it accurately.

Prostate Cancer: Extending the Evidence Beyond Breast and Colon

Two years before the Jedinak study, in 2006, Gu and Sivam tested oyster mushroom aqueous extract against PC-3 prostate cancer cells. PC-3 is an androgen-independent prostate cancer cell line, meaning it does not depend on male hormones to grow. Androgen-independent prostate cancer is the aggressive, hard-to-treat form that tends to appear after standard hormonal therapy stops working.

Their screen covered twenty edible mushroom species and three purified mushroom polysaccharides. The water-soluble oyster mushroom extract, which they abbreviated POE, was the most cytotoxic of everything tested. POE triggered apoptosis in PC-3 cells within two hours at 150 µg/mL, and both the cytotoxicity and the apoptosis were dose-dependent. The clearest numbers came from soft agar colony formation: tumor colony-forming efficiency fell to 4.5% at 60 µg/mL and to 0.5% at 120 µg/mL, against a POE-free medium defined as 100%.^[2]

This extends the anti-cancer cell pattern from breast and colon to a third cancer type, and again to an aggressive, therapy-resistant subtype. The same caveat applies: this is an in vitro observation, not clinical evidence.

The Temperature Finding Most Summaries Leave Out

Gu and Sivam also ran the experiment that matters most to anyone wondering whether a plate of sautéed oyster mushrooms carries any of this. They heated the extract before testing it. Activity survived a range of temperatures below 40°C. Two hours at 80°C eliminated it.^[2]

They also characterized what was doing the work. The active fraction, POE-F2, was heat-sensitive and absorbed strongly at 280 nm, the signature of protein. Their conclusion was that the active compounds recovered from P. ostreatus are water-soluble proteins or polypeptides, not the beta-glucan polysaccharides that dominate the marketing of mushroom supplements.^[2]

Temperature Window

The Active Fraction Does Not Survive Cooking

Gu and Sivam heated the extract before testing it. The compound behind the strongest anti-cancer result in this literature behaved like a protein, and it came apart well below the temperature of a hot pan.

Boiling

Sauté / roast

0°20°40°60°80°100°120°

Temperature (°C)

Activity retained

Stable across temperatures below 40 °C

Not reported

No intermediate temperature tested in the paper

Activity eliminated

Abolished by 2 hours at 80 °C

This applies to the heat-labile protein fraction, not to beta-glucans. In a separate analysis, blanching left beta-glucan content essentially unchanged while reducing polyphenols and antioxidant activity. Different compounds, different fates in the pan.

Sources: Gu YH, Sivam G. J Med Food. 2006;9(2):196–204 (PMID 16822205) — bioactivity “eliminated by exposure to high temperature (80 degrees C) for 2 hours; however, it remained stable at a series temperatures of below 40 degrees C.” Beta-glucan contrast from Lam YS, et al. Int J Med Mushrooms. 2015;17(2):117–28 (PMID 25746617). The 40–80 °C span was not tested. Cooking temperatures are standard culinary reference points, not study findings.

Cooking temperatures for sautéing, roasting, or boiling all sit far above 80°C. The proteins responsible for the strongest in vitro cytotoxicity in this literature are, on the evidence of the study that found them, unlikely to survive an ordinary kitchen. This does not mean cooked oyster mushrooms are nutritionally pointless, and it says nothing about beta-glucans, which are considerably more heat-stable. It does mean the specific laboratory finding people cite when they describe oyster mushrooms as cancer-killing is a finding about an unheated extract.

The 2022 Human Trial: What Spacek Found in Breast Cancer Patients

In 2022, Spacek and colleagues published the only human study involving oyster mushroom extract and cancer patients. It appeared in the journal Immunotherapy. The participants were patients with endocrine-dependent (hormone receptor-positive) breast cancer at clinical stages I and II, and every one of them was already in clinical and imaging remission. They received pleuran, the beta-glucan extracted from Pleurotus ostreatus.

Three features of the design set the ceiling on what it can show. The endpoint was the immune profile, not tumor response. The groups were unequal and not randomized: 49 patients took pleuran and 146 formed the control group. And because the patients were in remission, there was no measurable disease present for the supplement to act on.

What it found was a significant increase in the absolute numbers of CD3+, CD19+, CD4+ and CD8+ lymphocytes in the pleuran group relative to controls, measured by flow cytometry.^[5] Natural killer cells were among the cell populations counted, but an NK increase was not among the reported significant results, and NK cytotoxic activity was not what this study measured. The authors framed their conclusion as a suggestion of potential benefit for immune rehabilitation and prognosis, which is appropriately cautious language for an observational comparison of this size.

The finding should be read for what it is and is not. It shows that pleuran supplementation is associated with higher circulating lymphocyte counts in breast cancer patients in remission. It does not show that it kills cancer cells, slows tumor growth, prevents recurrence, or improves survival. Higher lymphocyte counts are a plausible intermediate on the path to better cancer outcomes, but they are a proxy, and the step from that proxy to clinical benefit is exactly the step this study did not take.

It remains the most clinically proximate evidence in the oyster mushroom cancer literature, which says as much about the thinness of that literature as it does about the study.

Which Compounds Drive the Effect?

Four compound classes come up repeatedly in discussions of oyster mushrooms and cancer. They are usually presented as a single list, as though the evidence behind them were interchangeable. It is not. Each one sits at a different level of proof, and the differences are larger than the similarities.

Evidence Audit

Four Compounds, Four Very Different Ceilings

These four are almost always listed together as the compounds behind oyster mushroom’s anti-cancer activity. Listed side by side with what actually backs each one, the list stops looking like a set.

Beta-glucans (pleuran)Human data
What supports it: Raised CD3+, CD19+, CD4+ and CD8+ lymphocyte counts in 49 breast cancer patients versus 146 controls.
Where it stops: Patients were already in remission, groups were not randomised, and no tumour outcome was measured.
Spacek 2022 [5]; Sreedharan 2025 [6]
LectinsAnimal tumours
What supports it: An isolated lectin slowed hepatoma H-22 and sarcoma S-180 tumours in mice and prolonged survival. Binds galactose-type sugars, a plausible basis for cancer-versus-normal selectivity.
Where it stops: No human data. The selectivity link to the 2008 cell-culture result is a hypothesis, never tested.
Wang, Gao & Ng 2000 [7]
ErgothioneinePopulation association
What supports it: Highest versus lowest mushroom intake associated with total cancer RR 0.66 (95% CI 0.55–0.78) across 17 observational studies.
Where it stops: The studies measured mushroom consumption, not ergothioneine. 11 of 17 were case-control, vulnerable to recall bias. Association is not causation.
Ba 2021 [8]
LovastatinNo anti-cancer evidence
What supports it: Reported in Pleurotus fruiting bodies in 1995. Statins as a drug class have separate anti-cancer research behind them.
Where it stops: A 2015 analysis could not detect lovastatin in P. ostreatus at all. No study has tested oyster mushroom lovastatin for anti-cancer activity in any model.
Gunde-Cimerman 1995 [9]; Lam 2015 [10]

The four-compound list is often credited to the 2025 Sreedharan review. That review’s full text does not mention lectins or lovastatin at any point. Each attribution above is taken from the paper that actually reports it.

Sources: Spacek J, et al. Immunotherapy. 2022;14(1):31–40 (PMID 34784798); Sreedharan PL, et al. Foods. 2025;14(1):128 (PMID 39796417); Wang H, Gao J, Ng TB. Biochem Biophys Res Commun. 2000;275(3):810–6 (PMID 10973803); Ba DM, et al. Adv Nutr. 2021;12(5):1691–1704 (PMID 33724299); Gunde-Cimerman N, et al. Exp Mycol. 1995;19(1):1–6; Lam YS, et al. Int J Med Mushrooms. 2015;17(2):117–28 (PMID 25746617).

Beta-glucan polysaccharides are the best-supported of the four, and the only class with human data. They are thought to work through immune activation rather than direct cytotoxicity: beta-glucans engage receptors on macrophages and other immune cells and enhance downstream immune signaling. A 2025 review in Foods by Sreedharan and colleagues surveys this mechanism at length, describing how oyster mushroom bioactives affect the maturation, differentiation, and proliferation of immune cells, and noting that the prebiotic effects of mushrooms may support quality of life during and after cancer therapy by restoring intestinal microbiota.^[6] Pleuran, an oyster mushroom beta-glucan, is the compound tested in the Spacek study above. For the deeper explanation of how mushroom polysaccharides activate immune cells, see How Mushroom Sugars Activate Cancer-Fighting Immune Cells.

Lectins have the most striking preclinical result and no human data at all. In 2000, Wang, Gao and Ng isolated a dimeric lectin from fresh oyster mushroom fruiting bodies and reported potent antitumor activity in mice bearing sarcoma S-180 and hepatoma H-22 tumors, with prolonged survival in the treated animals.^[7] This paper is the actual source of the "oyster mushrooms fight liver cancer" claim, and it is worth being precise about it: H-22 hepatoma was grown as a tumor in living mice, not as a hepatoma cell line in a dish.

The lectin's sugar-binding profile is also the best available mechanistic explanation for the selectivity theme running through this article. Its activity was blocked by melibiose, lactose, and D-galactose, meaning it recognizes galactose-type structures.^[7] Cancer cells frequently display altered galactose-type surface glycans relative to healthy tissue, which offers a plausible route by which a lectin could distinguish between them. Plausible is the correct word: no study has yet shown that this is why Jedinak's extract spared MCF-10A and FHC cells. Lectins are covered in depth in Oyster Mushroom Lectins and Anti-Cancer Activity and the companion selectivity article Oyster Mushroom Lectins and Selective Cancer Cell Cytotoxicity.

Ergothioneine is an antioxidant present in all mushrooms and relatively concentrated in oyster mushrooms. Its link to cancer is epidemiological, not experimental. A 2021 systematic review and meta-analysis of 17 observational studies found that people in the highest mushroom-consumption groups had a lower risk of cancer than those in the lowest, with a pooled relative risk of 0.66 (95% CI 0.55 to 0.78), and the association was statistically significant for breast cancer specifically.^[8] That is roughly a third lower risk in the highest-intake groups, not the 45% figure that circulates in secondary coverage. Two caveats travel with it: 11 of the 17 studies were case-control designs, which are vulnerable to recall and selection bias, and the analysis measured mushroom consumption, not ergothioneine. Ergothioneine is a proposed explanation for the association, not a measured exposure in it. For the ergothioneine angle specifically, see Ergothioneine in Oyster Mushrooms: The Longevity Antioxidant You Can Eat and Daily Mushroom Consumption and Cancer Risk Reduction.

Lovastatin is the weakest link in the chain, and it is routinely presented as though it were among the strongest. Statins as a drug class have genuine anti-cancer research behind them, and lovastatin has been identified in Pleurotus fruiting bodies: a 1995 paper reported that Pleurotus fruiting bodies contain this inhibitor of HMG-CoA reductase.^[9] But a 2015 analysis that set out to quantify lovastatin, beta-glucan, and polyphenols in raw and processed P. ostreatus reported plainly that lovastatin was not detected in the mushrooms they tested, while measuring beta-glucan at 23.9% of dry matter in the same samples.^[10]

So the honest position on lovastatin is narrower than the usual claim. Its presence in oyster mushrooms is inconsistent between analyses, its concentration when present is nowhere near a pharmacological statin dose, and no study has tested oyster mushroom lovastatin for anti-cancer activity in any model. Attributing part of the oyster mushroom cancer literature to lovastatin is an inference stacked on an inference.

Whether these compounds work independently or in concert is unresolved, and the studies are not designed to answer it. Most of the cell culture work uses crude extracts, testing everything at once. The one paper that did fractionate and chase the active component, Gu and Sivam, landed on a heat-labile protein rather than on any of the four classes above.^[2]

What Lab Studies Cannot Tell You: The Honest Evidence Ceiling

The oyster mushroom cancer research described here is real. The selectivity finding in Jedinak 2008 has been cited heavily, and the same cancer-versus-normal-cell pattern reappeared in a different species with a different purified compound in Yuan 2017, which is meaningful convergence even though neither study is a direct replication of the other. The Spacek study measured a change in real patients. The 2025 Sreedharan review situates all of it within an active research area.

But the gap between "inhibits cancer cell proliferation in cell culture" and "treats or prevents cancer in people" is one of the largest in all of biomedical research. Cancer drugs that showed exactly these patterns in cell culture and animal models have failed in human trials at high rates. The biology of a cancer in a living person is vastly more complex than a cancer cell line growing in a laboratory dish.

Three specific limits are worth holding onto. The concentrations that killed cancer cells in culture were applied directly to those cells, and no study has established what, if anything, reaches a tumor after a person eats a mushroom or swallows a capsule. The most potent activity found in this literature is carried by proteins that do not survive cooking. And the one human study enrolled patients who were already in remission and counted immune cells rather than tracking whether their cancer came back.

The Sreedharan review frames oyster mushrooms as a candidate for complementary cancer therapy, meaning use alongside established treatment, not as a replacement for it, and calls explicitly for more clinical research.^[6] That framing is the one the evidence currently supports.

No evidence supports the claim that eating oyster mushrooms treats cancer in humans.

This article is a review of published research and is not medical advice. Nothing here should be used to delay, replace, or modify cancer treatment. Concentrated mushroom extracts are not equivalent to food, and supplements can interact with chemotherapy, endocrine therapy, and immunotherapy. Anyone with a cancer diagnosis should talk to their oncologist before starting any mushroom supplement.

The Bottom Line

Oyster mushroom extract inhibited breast (MCF-7, MDA-MB-231) and colon (HT-29, HCT-116) cancer cells while leaving matched normal cells unaffected in a single 2008 experiment; separate older papers cover prostate cells (PC-3) and, in mice rather than cell culture, hepatoma tumors treated with an oyster mushroom lectin. The most cytotoxic fraction is a heat-labile protein destroyed by two hours at 80°C, well below cooking temperatures. The only human study raised lymphocyte counts in stage I-II breast cancer patients already in remission, with no tumour endpoint. The four compound classes usually credited rest on very unequal evidence, and lovastatin in particular has no anti-cancer data in oyster mushrooms and was undetectable in one analysis. No human trial has demonstrated cancer treatment efficacy.

Frequently Asked Questions

In laboratory cell culture studies, oyster mushroom extract inhibits the proliferation of breast, colon, and prostate cancer cells, and an oyster mushroom lectin slowed hepatoma tumours in mice. The 2008 Jedinak study found the breast and colon inhibition occurred without affecting matched normal cells. The only human study (Spacek 2022) enrolled breast cancer patients already in remission and measured immune cell counts, not cancer outcomes. There is no clinical trial evidence that oyster mushroom supplementation treats or prevents cancer in humans.

The research shows: (1) oyster mushroom extract suppresses breast, colon, and prostate cancer cells in cell culture, including aggressive subtypes like triple-negative breast cancer and androgen-independent prostate cancer; (2) animal data exists for King Oyster protein in colon cancer and for an oyster mushroom lectin in mouse hepatoma and sarcoma; (3) one human study found beta-glucan from oyster mushroom raised lymphocyte counts in breast cancer patients in remission; (4) the compound classes credited for this activity rest on very unequal evidence. The findings are mechanistically interesting but have not translated to human cancer treatment trials.

Four are usually listed, but their evidence differs sharply. Beta-glucan polysaccharides have the only human data (raised lymphocyte counts in remission patients). Lectins have the strongest animal data, slowing hepatoma and sarcoma tumours in mice, and bind galactose-type sugars in a way that could plausibly explain cancer-versus-normal selectivity. Ergothioneine has only population-level association, from studies that measured mushroom intake rather than ergothioneine itself. Lovastatin has no anti-cancer evidence in oyster mushrooms at all, and one 2015 analysis could not detect it in P. ostreatus. Separately, the most cytotoxic fraction ever isolated from oyster mushrooms was a heat-labile protein, not any of these four.

Oyster mushroom extract inhibited breast cancer cell proliferation in cell culture, including both hormone-positive MCF-7 cells and triple-negative MDA-MB-231 cells, without affecting normal breast cells in the same experiment (Jedinak 2008). The Spacek 2022 study found pleuran raised CD3+, CD19+, CD4+ and CD8+ lymphocyte counts in stage I-II breast cancer patients who were already in remission, compared with a larger untreated control group. It was not randomised and measured no tumour outcome. Whether any of this translates to clinical benefit is unknown. Anyone in treatment for breast cancer should consult their oncologist before taking mushroom supplements, which can interact with endocrine and other therapies.

Breast cancer (MCF-7 and MDA-MB-231 cell lines), colon cancer (HT-29 and HCT-116), androgen-independent prostate cancer (PC-3), and liver cancer (hepatoma H-22 grown as tumours in mice, treated with an isolated oyster mushroom lectin, alongside sarcoma S-180 in the same study). The related species Pleurotus eryngii (King Oyster) has been tested against colon cancer in both cell culture and mouse models. All of this is preclinical. The only cancer type with published human data is breast cancer (Spacek 2022; an immune-profile endpoint in patients in remission, not a cancer treatment outcome).

For the most potent fraction identified in this literature, yes. Gu and Sivam (2006) found the cytotoxic activity of oyster mushroom extract against prostate cancer cells remained stable below 40°C but was eliminated by two hours at 80°C, and they characterised the active component as a water-soluble protein or polypeptide. Ordinary sautéing, roasting, and boiling all exceed 80°C. Beta-glucans are considerably more heat-stable and are not affected in the same way, but the specific proteins behind the strongest in vitro results are unlikely to survive normal cooking. No study has tested whether these proteins survive digestion even when eaten raw.

Sources & References

1RTHM-00257·Jedinak, Andrej et al. (2008). “Pleurotus ostreatus inhibits proliferation of human breast and colon cancer cells through p53-dependent as well as p53-independent pathway..” International journal of oncology.Study breakdown →PubMed →↩
2RTHM-00183·Gu, Yu-Huan et al. (2006). “Cytotoxic effect of oyster mushroom Pleurotus ostreatus on human androgen-independent prostate cancer PC-3 cells..” Journal of medicinal food.Study breakdown →PubMed →↩
3RTHM-00932·Yuan, Biao et al. (2017). “In vitro and in vivo inhibitory effects of a Pleurotus eryngii protein on colon cancer cells..” Food & function.Study breakdown →PubMed →↩
4RTHM-00664·Wong, Jack Ho et al. (2020). “Mushroom extracts and compounds with suppressive action on breast cancer: evidence from studies using cultured cancer cells, tumor-bearing animals, and clinical trials..” Applied microbiology and biotechnology.Study breakdown →PubMed →↩
5RTHM-01617·Spacek, Jan et al. (2022). “Immunomodulation with β-glucan from Pleurotus ostreatus in patients with endocrine-dependent breast cancer..” Immunotherapy.Study breakdown →PubMed →↩
6RTHM-02186·Sreedharan, Priya Lakshmi et al. (2025). “The Emerging Role of Oyster Mushrooms as a Functional Food for Complementary Cancer Therapy..” Foods (Basel.Study breakdown →PubMed →↩
7RTHM-00074·Wang, H et al. (2000). “A new lectin with highly potent antihepatoma and antisarcoma activities from the oyster mushroom Pleurotus ostreatus..” Biochemical and biophysical research communications.Study breakdown →PubMed →↩
8RTHM-00671·Ba, Djibril M et al. (2021). “Higher Mushroom Consumption Is Associated with Lower Risk of Cancer: A Systematic Review and Meta-Analysis of Observational Studies..” Advances in nutrition (Bethesda.Study breakdown →PubMed →↩
9RTHM-00016·Gunde-Cimerman, N et al. (1995). “Pleurotus fruiting bodies contain the inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase-lovastatin..” Experimental mycology.Study breakdown →PubMed →↩
10RTHM-00384·Lam, Yu Shan et al. (2015). “Determination of Lovastatin, β-glucan, Total Polyphenols, and Antioxidant Activity in Raw and Processed Oyster Culinary-Medicinal Mushroom, Pleurotus ostreatus (Higher Basidiomycetes)..” International journal of medicinal mushrooms.Study breakdown →PubMed →↩